News 
Contact Us
No. 18, Fuyuan Road, Tianjin Wuqing Development Area, China
【Urban Media Focus】AcornMed New Test Kits Launched Three Years Ahead of Schedule
Recently,
Tianjin News reported:
Focusing on Beijing-Tianjin-Hebei: New test kits launched three years ahead of schedule
Focused on reporting
Enterprises in Wuqing Development Area
AcornMed
Let's take a look together~
Tianjin North Network News: Last November, the Beijing Tianjin Hebei Industrial Chain Supply Chain Conference was held in Beijing, and the three cities jointly released the industrial chain map for the first time. The six industrial chains are bio medicine, hydrogen energy, network security and industrial Internet, high-end industrial machines, new energy and intelligent connected vehicles, and robots. Starting today, let's sort out these six industrial chains one by one and see what achievements have been made in strengthening scientific and technological innovation collaboration and industrial system integration in the Beijing Tianjin Hebei region over the past six months? Today, looking at the biopharmaceutical industry chain, the three regions are working together to launch a new product three years ahead of schedule.
AcornMed incubated at Peking University in 2018, is a company specializing in the production of genetic testing products. Today, the latest developed tumor detection reagent kit has obtained a medical device license and will be put into the market next month, filling the gap in the field of urinary system tumor detection in China. From project approval to mass production, this product was launched three years earlier than expected. Behind the acceleration, it is thanks to the joint construction of the biopharmaceutical industry chain map by the Beijing Tianjin Hebei region in November last year. Beijing leverages its advantages in original innovation strategies, Tianjin provides excellent service support for precision manufacturing and technology transformation, Hebei accelerates the development of high-end raw and auxiliary materials, and the three regions cooperate, share, and develop in a staggered manner.
AcornMed settled its production and transformation base in Wuqing, Tianjin in 2019, less than 70 kilometers away from its Beijing headquarters. In addition to geographical advantages, what enterprises value more is the clustering of Tianjin biopharmaceutical industry related enterprises and a complete production chain. After the construction of the chain at the end of last year, the docking between Beijing and Tianjin became more frequent, at least once a week. Based on the research and development progress of research institutes in universities such as Peking University and the Chinese Academy of Sciences, as well as the latest clinical feedback, Tianjin made an adjustment plan for production conversion.
The Municipal Science and Technology Bureau is synchronously following the Tianjin biopharmaceutical industry chain to assist AcornMed in connecting with relevant supporting enterprises such as Lino, Zhiyuan, and Jinkey Biotechnology in the Beijing Tianjin Industrial New City. Taking the upcoming tumor detection kit as an example, at least 25000 genes need to be sequenced and validated one by one before its launch. Among them, more than 70% were completed nearby in Tianjin, which has accelerated the process for at least six months. In February this year, Tianda Synthetic Biology Frontier Research Institute, located 3 kilometers away from AcornMed, opened a new laboratory that can provide more efficient testing services.
As of now, the biopharmaceutical industry chain map of the Beijing-Tianjin-Hebei-region has gathered more than 5300 related enterprises, forming four sub chains of chemical medicine, traditional Chinese medicine, biopharmaceuticals, and medical devices. AcornMed has found a customized supplier of raw materials in the Hebei Cangzhou Biomedical Industry Park, which has accelerated the launch of new products.
At present, the Beijing Municipal Bureau of Economy and Information Technology is working on formulating an action plan for the implementation of the Beijing-Tianjin-Hebei Biomedical Industry Chain Map, further refining the division of labor. Among them, Tianjin will guide through policies to do a good job in instrument and equipment sharing, testing and verification platform construction, technology transfer and transformation services, etc. (Jin Yun News Editor Zhang Qilin)
Source：Jin Yun
Release Time：2024-05-22 11:02:00
Home